Stephen Goding Email & Phone Number

New York City Metropolitan Area

Pearl River, NY

• Designed and independently performed in vivo anti-tumor efficacy studies, ex vivo processing of lymphoid organs for analysis and adoptive transfer, and monitoring of tumor growth response and rechallenges in.
• Designed flow cytometry panels and performed flow analysis on murine tumors and tissues to characterize immune cell composition.
• Implemented in life survival studies involving a luciferase-expressing lung tumor metastases model to monitor the anti-tumor efficacy of immune-modulating compounds.
• Performed luminescence IVIS imaging of IFNb-reporter mice to complement nucleic acid-sensing projects.

• Determined anti-LAG3 to be superior to anti-PD-L1 as a supplemental antibody monotherapy of transgenic CD4 T cell, resulting in significantly fewer relapses in wild-type mice.
• Identified a greater negative role of host PD-L1 in the exhaustion of tumor / self-antigen specific T cells than that induced by tumor-expressed PD-L1. Increased survival of tumor-bearing mice when made deficient for.
• Created tumor / self-antigen, TRP-1, deficient wild-type mice to assess the effect of tumor antigen alone against shared tumor / self-antigen on CD4 T cells in immunocompetent mice.

• Obtained a DoD Post Doc Visionary Award grant that funded work published in the Journal of Immunology, cited greater than 100 times.
• Identified exhaustion of transgenic tumor / self-antigen specific CD4 T cells with flow cytometry and cytokine / chemokine ELISAs.
• Planned and conducted in vivo studies on the reversal of T cell exhaustion to treat relapsing melanoma with inhibitory receptor antibody therapy. Determined anti-PD-L1 and anti-LAG3 dual antibody therapy to be.
• Developed and optimized a more reliable model of melanoma relapse, thereby greatly decreasing the number of mice needed to obtain consistent recurrence and amount of time for relapse to occur - recurrence rate went.

Baltimore, Maryland Area